Home / Latest Science News -- ScienceDaily / Immunotherapy -- targeted drug combination improves survival in advanced kidney cancer

Immunotherapy -- targeted drug combination improves survival in advanced kidney cancer

Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug according to the results from a phase 3 clinical trial.

from Latest Science News -- ScienceDaily https://www.sciencedaily.com/releases/2021/02/210213150230.htm
Immunotherapy -- targeted drug combination improves survival in advanced kidney cancer Immunotherapy -- targeted drug combination improves survival in advanced kidney cancer Reviewed by cmakigo on February 14, 2021 Rating: 5

You May Also Like

No comments:

Post a Comment

Subscribe to: Post Comments ( Atom )
'; (function() { var dsq = document.createElement('script'); dsq.type = 'text/javascript'; dsq.async = true; dsq.src = '//' + disqus_shortname + '.disqus.com/embed.js'; (document.getElementsByTagName('head')[0] || document.getElementsByTagName('body')[0]).appendChild(dsq); })();
Powered by Blogger.